AIS Biotech
A biotech company with the objective of developing a new class of sugar-based anti-infective biotherapeutics to fight (re)emerging infectious diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | €1.5m | Seed | |
| Total Funding | 000k | ||
Related Content
AIS Biotech, a French biotechnology startup founded in March 2023, is pioneering a novel approach to combating infectious diseases. The company specializes in developing sugar-based anti-infective biotherapeutics, which are essentially medicines derived from sugars that can fight infections. These biotherapeutics act as decoy receptors, preventing harmful pathogens like viruses and bacteria from attaching to and infecting human cells.
AIS Biotech operates in the biopharmaceutical market, focusing on creating sustainable and eco-friendly solutions. Their innovative technology mimics the natural receptors on cell surfaces, using glycomimetics—sugar molecules that imitate cell receptors—to neutralize pathogens. This approach not only helps in fighting infections but also reduces the reliance on traditional, petrochemical-based methods, thereby promoting environmental sustainability.
The company's business model revolves around the development and commercialization of these sugar-based therapies. They generate revenue through the sale of their biotherapeutic products and potentially through partnerships or licensing agreements with larger pharmaceutical companies. AIS Biotech's primary clients include healthcare providers, hospitals, and potentially other biotech firms looking for innovative anti-infective solutions.
AIS Biotech is committed to expanding its product pipeline beyond its initial offering, GLYCOFLU, to include a variety of new sugar-based therapies. Their sustainable bioproduction process not only preserves natural resources but also reduces costs and accelerates the development of greener products. This positions AIS Biotech as a forward-thinking company in the fight against both current and emerging infectious diseases.
In summary, AIS Biotech is a promising startup in the biotech sector, leveraging innovative sugar-based technologies to create sustainable and effective anti-infective therapies.
Keywords: biotech, anti-infective, sugar-based, biotherapeutics, pathogens, glycomimetics, sustainable, bioproduction, healthcare, innovation.